Cover Image
市場調查報告書

異位性皮膚炎:開發平台分析

Atopic Dermatitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232797
出版日期 內容資訊 英文 382 Pages
訂單完成後即時交付
價格
Back to Top
異位性皮膚炎:開發平台分析 Atopic Dermatitis - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 382 Pages
簡介

異位性皮膚炎是皮膚變癢的發炎,也有慢性的症狀拖長,伴隨氣喘和花粉症。 症侯有紅色到帶茶色的灰色斑點,發癢,尤其是夜間變得厲害。有小小隆起的疙瘩,抓的話會有體液流出變成瘡痂,肥厚性的鱗狀皮膚,抓的話潰爛變敏感的皮膚等。

本報告提供異位性皮膚炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍
  • 異位性皮膚炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Abeome Corporation
  • Accolade Pharmaceuticals, LLC
  • AlbireoPharma
  • Almirall, S.A.
  • Amgen Inc.
  • Amorepacific Corporation
  • Anacor Pharmaceuticals, Inc.
  • AnaMar AB
  • AnaptysBio, Inc.
  • AnGes MG, Inc.
  • Aquinox Pharmaceuticals Inc.
  • arGEN-X BV
  • Blueberry Therapeutics Ltd
  • Brickell Biotech, Inc.
  • Celgene Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • 中外製藥
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Dr. August Wolff GmbH & Co. KG Arzneimittle
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Ferrer Internacional, S.A.
  • Han Wha Pharma Co., Ltd.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Immune Pharmaceuticals Inc.
  • Inflamalps SA
  • 日本煙草產業
  • Johnson & Johnson
  • Kineta, Inc.
  • LegoChem Biosciences, Inc
  • LEO Pharma A/S
  • Madam Therapeutics B.V.
  • MedImmune, LLC
  • NeoPharm Co., Ltd.
  • Novan, Inc.
  • Novartis AG
  • Orbis Biosciences, Inc.
  • 大塚集團
  • Oxagen Limited
  • Pfizer Inc.
  • Pharis Biotec GmbH
  • Pharmedartis GmbH
  • Provectus Biopharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Signum Dermalogix, Inc
  • Spherium Biomed S.L.
  • sterna biologicals Gmbh & Co KG
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • SWITCH Biotech LLC
  • 武田藥品工業
  • Thesan Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Vicore Pharma AB
  • Vitae Pharmaceuticals, Inc.
  • VivaCell Biotechnology Espana S.L.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • A-3914
  • A-5425
  • AKP-11
  • ALX-101
  • AM-1030
  • AN-4161
  • ANB-020
  • apremilast
  • 異位性皮膚炎用Galectin-3抑制適體
  • AQX-1125
  • ARGX-112
  • ARN-077
  • baricitinib
  • BB-2702
  • BBI-2000
  • BBI-5000
  • bertilimumab
  • 異位性皮膚炎、皮膚炎用生技藥品
  • C-21
  • CBP-174
  • CBP-201
  • CCX-6239
  • CDE-001
  • Cis-Urocanic Acid
  • CNTO-7160
  • kobamamido
  • crisaborole
  • CT-101
  • CT-1x1
  • CT-1x2
  • CT-1x3
  • CT-327
  • CT-340
  • Cyclosporine
  • dalazatide
  • DMT-210
  • DRM-02
  • 異位性皮膚炎治療藥
  • 異位性皮膚炎用 TNFR-1拮抗劑
  • deyupirumabu
  • FB-825
  • fevipiprant
  • FIB-116
  • Furestem-AD
  • GBR-830
  • Histimex
  • HS-378
  • JTE-052
  • KPI-150
  • LCB-030110
  • lebrikizumab
  • LEKTI-6
  • LEO-32731
  • LEO-39652
  • mepolizumab
  • MLR-1130
  • mometasone furoate
  • 氣喘、線維症、異位性皮膚炎用 IL-25抑制單株抗體
  • 異位性皮膚炎用 IL-4/IL-13抑制單株抗體
  • 發炎性用腸道疾病、 異位性皮膚炎、大腸癌 Th22細胞/IL-22途徑標的單株抗體
  • N-oleoylethanolamine
  • nemolizumab
  • NPH-12
  • OC-000459
  • OC-2417
  • octenidine hydrochloride
  • OLX-103
  • omiganan pentahydrochloride
  • OPA-15406
  • P-10
  • PAC-14028
  • PDI-192
  • 異位性皮膚炎用 CX3CR1拮抗肽
  • 異位性皮膚炎用 TNFR-1拮抗肽
  • PH-10
  • PL-601
  • PMA-101R
  • PMA-201
  • PMA-411R
  • prednisone
  • PZ-235
  • Q-301
  • Qi-507
  • roflumilast
  • RTU-1096
  • RVT-501
  • S-414114
  • SB-011
  • SB-414
  • SIG-1311
  • SIG-1322
  • 異位性皮膚炎用 S1PR1調整藥
  • 異位性皮膚炎用小分子
  • SP-14019
  • SUN-0597
  • SWT-01113
  • SWT-05141
  • 免疫學、皮膚疾病、遺傳性疾病用激肽釋放酶抑制合成肽
  • tacrolimus
  • tezepelumab
  • tofacitinib
  • tralokinumab
  • ustekinumab
  • VTP-38543
  • WBI-1001
  • WOL-071007
  • XmAb-7195
  • YJC-10592
  • Zafi-1
  • ZPL-3893787
  • ZPL-5212372

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9627IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 40, 20, 1, 47, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Atopic Dermatitis - Overview
  • Atopic Dermatitis - Therapeutics Development
  • Atopic Dermatitis - Therapeutics Assessment
  • Atopic Dermatitis - Companies Involved in Therapeutics Development
  • Atopic Dermatitis - Drug Profiles
  • Atopic Dermatitis - Dormant Projects
  • Atopic Dermatitis - Discontinued Products
  • Atopic Dermatitis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Atopic Dermatitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Atopic Dermatitis - Pipeline by AbbVie Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Abeome Corp, H2 2017
  • Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals LLC, H2 2017
  • Atopic Dermatitis - Pipeline by Albireo Pharma Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Allergan Plc, H2 2017
  • Atopic Dermatitis - Pipeline by Almirall SA, H2 2017
  • Atopic Dermatitis - Pipeline by Amgen Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Amorepacific Corp, H2 2017
  • Atopic Dermatitis - Pipeline by AnaptysBio Inc, H2 2017
  • Atopic Dermatitis - Pipeline by AnGes MG Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Antibiotx ApS, H2 2017
  • Atopic Dermatitis - Pipeline by Asana BioSciences LLC, H2 2017
  • Atopic Dermatitis - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Bioleaders Corp, H2 2017
  • Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Brickell Biotech Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Celgene Corp, H2 2017
  • Atopic Dermatitis - Pipeline by ChemoCentryx Inc, H2 2017
  • Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2017
  • Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Clevexel Pharma SAS, H2 2017
  • Atopic Dermatitis - Pipeline by Cutanea Life Sciences Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Dermala Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017
  • Atopic Dermatitis - Pipeline by DURECT Corp, H2 2017
  • Atopic Dermatitis - Pipeline by Eli Lilly and Company, H2 2017
  • Atopic Dermatitis - Pipeline by Exicure Inc, H2 2017
  • Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Fountain Biopharma Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Galapagos NV, H2 2017
  • Atopic Dermatitis - Pipeline by Galectin Therapeutics Inc, H2 2017
  • Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by GTx Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Han Wha Pharma Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2017
  • Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2017
  • Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Incyte Corp, H2 2017
  • Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2017
  • Atopic Dermatitis - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Japan Tobacco Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Kang Stem Biotech Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by KPI Therapeutics Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2017
  • Atopic Dermatitis - Pipeline by Madam Therapeutics BV, H2 2017
  • Atopic Dermatitis - Pipeline by MedImmune LLC, H2 2017
  • Atopic Dermatitis - Pipeline by NeoPharm Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Novan Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Novartis AG, H2 2017
  • Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Otsuka Holdings Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Oxagen Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Pfizer Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2017
  • Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2017
  • Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Qurient Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Realm Therapeutics Plc, H2 2017
  • Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Sienna Biopharmaceuticals Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Signum Biosciences Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Spherium Biomed SL, H2 2017
  • Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2017
  • Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Switch Biotech LLC, H2 2017
  • Atopic Dermatitis - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017
  • Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
  • Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana SL, H2 2017
  • Atopic Dermatitis - Pipeline by Xencor Inc, H2 2017
  • Atopic Dermatitis - Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2017
  • Atopic Dermatitis - Dormant Projects, H2 2017
  • Atopic Dermatitis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Atopic Dermatitis - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Atopic Dermatitis - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Atopic Dermatitis - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Atopic Dermatitis - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Atopic Dermatitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Atopic Dermatitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top